bimekizumab,adalimumab
ucb pharmaceuticals,abbvie
['adalimumab', ' psa', 'be optimal', 'bimekizumab']
be optimal study - bimekizumab (il-17a and il-17f inhibitor) for treatment of psa. similar acr 50 (~50%) response rates of bimekizumab, adalimumab, and placebo (switched to bkz at wk 16). ~60% pasi100 in bkz
#acrbest abs#l02 #acr22 
Rheumatologist. Amateur chef. YNWA. Views and opinions are my own.